HER2 EXPRESSING SOLID TUMORS
Clinical trials for HER2 EXPRESSING SOLID TUMORS explained in plain language.
Never miss a new study
Get alerted when new HER2 EXPRESSING SOLID TUMORS trials appear
Sign up with your email to follow new studies for HER2 EXPRESSING SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene therapy breakthrough targets Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis early-stage trial tests a new gene therapy called VNX-202 in 27 adults with HER2-positive solid tumors. The study aims to see if the treatment is safe and can shrink tumors or slow their growth. Participants must have advanced cancer that has worsened after standard treatmen…
Matched conditions: HER2 EXPRESSING SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
New drug MT-304 targets Hard-to-Treat HER2 cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called MT-304, given alone or with another drug (nivolumab), in adults with advanced HER2-expressing solid tumors. The main goals are to check safety and find the best dose. About 60 participants will receive the treatment every two to four…
Matched conditions: HER2 EXPRESSING SOLID TUMORS
Phase: PHASE1 • Sponsor: Myeloid Therapeutics • Aim: Disease control
Last updated May 05, 2026 11:53 UTC